{
    "clinical_study": {
        "@rank": "146454", 
        "arm_group": [
            {
                "arm_group_label": "Cohort 1 Arm ABDC: BMS-955176 (Treatment A, B, D and C)", 
                "arm_group_type": "Experimental", 
                "description": "BMS-955176 single dose by mouth as specified"
            }, 
            {
                "arm_group_label": "Cohort 1 Arm BCDA: BMS-955176 (Treatment B, C, D and A)", 
                "arm_group_type": "Experimental", 
                "description": "BMS-955176 single dose by mouth as specified"
            }, 
            {
                "arm_group_label": "Cohort 1 Arm DABC: BMS-955176 (Treatment D, A, B and C)", 
                "arm_group_type": "Experimental", 
                "description": "BMS-955176 single dose by mouth as specified"
            }, 
            {
                "arm_group_label": "Cohort 1 Arm CDAB: BMS-955176 (Treatment C, D, A and B)", 
                "arm_group_type": "Experimental", 
                "description": "BMS-955176 single dose by mouth as specified"
            }, 
            {
                "arm_group_label": "Cohort 2 Arm EFGH: BMS-955176 (Treatment E, F, G and H)", 
                "arm_group_type": "Experimental", 
                "description": "BMS-955176 single dose by mouth as specified"
            }, 
            {
                "arm_group_label": "Cohort 2 Arm FGHE: BMS-955176 (Treatment F, G, H and E)", 
                "arm_group_type": "Experimental", 
                "description": "BMS-955176 single dose by mouth as specified"
            }, 
            {
                "arm_group_label": "Cohort 2 Arm HEFG: BMS-955176 (Treatment H, E, F and G)", 
                "arm_group_type": "Experimental", 
                "description": "BMS-955176 single dose by mouth as specified"
            }, 
            {
                "arm_group_label": "Cohort 2 Arm GHEF: BMS-955176 (Treatment G, H, E and F)", 
                "arm_group_type": "Experimental", 
                "description": "BMS-955176 single dose by mouth as specified"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to select the best dose level (amount of drug given) and best\n      formulation of the study drug (BMS-955176) to develop further."
        }, 
        "brief_title": "Relative Bioavailability Study With BMS-955176", 
        "completion_date": {
            "#text": "July 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "HIV/AIDS", 
        "detailed_description": {
            "textblock": "Primary Purpose: Other: This study will assess the bioavailability of BMS-955176 from a\n      micronized crystalline (MC) tablet relative to a spray-dried dispersion (SDD) suspension.\n      Assessment of additional experimental formulations relative to the micronized crystalline\n      tablet will also be performed"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "For more information regarding BMS clinical trial participation, please visit\n        www.BMSStudyConnect.com.\n\n        Inclusion Criteria:\n\n          -  Healthy subjects as determined by no clinically significant deviation from normal in\n             medical history, physical examinations, vital sign measurements, 12-lead\n             electrocardiogram (ECG) measurements and clinical laboratory test results\n\n          -  Body mass index (BMI) of 18.0 to 32.0 kg/m2, inclusive. BMI = Weight (kg) / [height\n             (m)]2\n\n          -  Men and women, ages 18 to 50 years, inclusive\n\n          -  Women must not be of childbearing potential, must not be breastfeeding\n\n        Exclusion Criteria:\n\n          -  Any significant acute or chronic medical illness\n\n          -  History of cardiac disease or clinically significant cardiac arrhythmias\n\n          -  Current or recent (within 3 months of study drug administration) gastrointestinal\n             disease\n\n          -  Any major surgery within 4 weeks of study drug administration\n\n          -  Any gastrointestinal surgery (including cholecystectomy) that could impact upon the\n             absorption of study drug"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "50 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "32", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 21, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02095886", 
            "org_study_id": "AI468-034", 
            "secondary_id": "2013-004896-10"
        }, 
        "intervention": {
            "arm_group_label": [
                "Cohort 1 Arm ABDC: BMS-955176 (Treatment A, B, D and C)", 
                "Cohort 1 Arm BCDA: BMS-955176 (Treatment B, C, D and A)", 
                "Cohort 1 Arm DABC: BMS-955176 (Treatment D, A, B and C)", 
                "Cohort 1 Arm CDAB: BMS-955176 (Treatment C, D, A and B)", 
                "Cohort 2 Arm EFGH: BMS-955176 (Treatment E, F, G and H)", 
                "Cohort 2 Arm FGHE: BMS-955176 (Treatment F, G, H and E)", 
                "Cohort 2 Arm HEFG: BMS-955176 (Treatment H, E, F and G)", 
                "Cohort 2 Arm GHEF: BMS-955176 (Treatment G, H, E and F)"
            ], 
            "intervention_name": "BMS-955176", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "March 21, 2014", 
        "number_of_arms": "8", 
        "official_title": "Assessment of BMS-955176 Bioavailability From a Micronized Crystalline Tablet Relative to a Spray-Dried Dispersion Suspension and Assessment of Additional Experimental Formulations Relative to the Micronized Crystalline Tablet in Healthy Subjects", 
        "overall_official": {
            "affiliation": "Bristol-Myers Squibb", 
            "last_name": "Bristol-Myers Squibb", 
            "role": "Study Director"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "United Kingdom: Ministry of Health", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "July 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Maximum observed plasma concentration (Cmax) of BMS-955176", 
                "safety_issue": "No", 
                "time_frame": "Days 1-4 of Periods 1, 2, 3 and 4"
            }, 
            {
                "measure": "Area under the plasma concentration-time curve from time zero extrapolated to infinite time [AUC(INF)] of BMS-955176", 
                "safety_issue": "No", 
                "time_frame": "Days 1-4 of Periods 1, 2, 3 and 4"
            }, 
            {
                "measure": "Area under the plasma concentration-time curve from time zero to 72 hours post-dose [AUC(0-72)] of BMS-955176", 
                "safety_issue": "No", 
                "time_frame": "Days 1-4 of Periods 1, 2, 3 and 4"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02095886"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Time of maximum observed plasma concentration (Tmax) of BMS-955176", 
                "safety_issue": "No", 
                "time_frame": "Days 1-4 of Periods 1, 2, 3 and 4"
            }, 
            {
                "measure": "Terminal plasma half-life (T-HALF) of BMS-955176", 
                "safety_issue": "No", 
                "time_frame": "Days 1-4 of Periods 1, 2, 3 and 4"
            }, 
            {
                "measure": "Apparent total body clearance (CLT/F) of BMS-955176", 
                "safety_issue": "No", 
                "time_frame": "Days 1-4 of Periods 1, 2, 3 and 4"
            }, 
            {
                "measure": "Safety and tolerability based on incidence of adverse events (AEs), serious AEs, AEs leading to discontinuation and deaths, marked abnormalities in clinical laboratory tests, vital sign measurements, ECGs and physical examinations", 
                "safety_issue": "Yes", 
                "time_frame": "Up to Period 4/Day 4 (discharge)"
            }
        ], 
        "source": "Bristol-Myers Squibb", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Bristol-Myers Squibb", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}